Embecta Corp.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Embecta Corp. (EMBC) director Morris Milton Mayo filed a Form 144 to sell 6,293 shares, worth $36,891, acquired as director compensation on February 7, 2024. The sale will be executed through RBC Capital Markets on NASDAQ.
Embecta Corp. (NASDAQ:EMBC) is facing a securities fraud class action, according to Bleichmar Fonti & Auld LLP. The suit alleges Embecta misrepresented the strength of its insulin pen needle category, tied to a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance and dividend was cut from $0.15 to $0.01.
Embecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.
Over the past 7 days, alphai's AI scored 1 news story mentioning EMBC (Embecta Corp.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EMBC coverage spans insider activity, earnings and regulation.
In the last 30 days, EMBC insiders filed 4 SEC Form 4 transactions — 4 purchases ($558K) and no sales. The most active reporter was HOMBACH ROBERT J. with 1 filing.
Minor insider sell may exert slight downward pressure.
The lawsuit centers on alleged misrepresentations around insulin pen needle demand and guidance, which can increase litigation risk and investor discounting.
Guidance raises (EPS and operating margin) and margin deterioration vs prior year create a mixed near-term setup, but the reaffirmed revenue range plus higher profitability outlook can support sentiment.
Guidance raises and margin improvement signals better cost structure and integration progress, supporting a more constructive earnings outlook.
Insider open-market buying by the CEO is a modest positive signal, but it is not a fundamental catalyst like earnings or guidance.
alphai scores every news story that mentions EMBC with an AI model for sentiment and relevance, and aggregates insider trades from Embecta Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Embecta Corp. (EMBC) director Morris Milton Mayo filed a Form 144 to sell 6,293 shares, worth $36,891, acquired as director compensation on February 7, 2024. The sale will be executed through RBC Capital Markets on NASDAQ.
1 min readEmbecta Corp. (NASDAQ:EMBC) is facing a securities fraud class action, according to Bleichmar Fonti & Auld LLP. The suit alleges Embecta misrepresented the strength of its insulin pen needle category, tied to a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance and dividend was cut from $0.15 to $0.01.
4 min readEmbecta (NASDAQ:EMBC) held its FY2026 Q3 earnings call. Revenue was $271.7M, down 8.1% YoY, with U.S. revenue down 24.6% and international up 11.5% on Owen Mumford strength. Adjusted EPS was $0.56. Free cash flow was $41M. FY2026 guidance: revenue $1.015B-$1.035B, adjusted EPS $1.80-$1.90, margin 23.5%-24%.
10 min readEmbecta (EMBC) reported Q3 FY2026 revenue of $271.7 million, down 8.1% YoY, with U.S. revenue down 24.6% and international revenue up 11.5%. Adjusted EPS was $0.56. The company raised FY2026 adjusted operating margin guidance to 23.5% to 24% and EPS to $1.80 to $1.90, reaffirming revenue guidance of $1.015B to $1.035B.
6 min readKurdikar Devdatt (President and CEO) purchased 30,000 shares of Embecta Corp. (EMBC) at $4.70 ($0.14M total) on 2026-08-12.
2 min readElguicze Jacob (SVP and CFO) purchased 20,000 shares of Embecta Corp. (EMBC) at $4.67 on 2026-08-12.
1 min readMann Jeffrey Z (Pres, Pharm Svc&Prod Mgmt, CLO) purchased 20,000 shares of Embecta Corp. (EMBC) at $4.99 on 2026-08-12.
2 min readHOMBACH ROBERT J. purchased 45,000 shares of Embecta Corp. (EMBC) at $4.97 ($0.22M total) on 2026-08-12.
1 min readBleichmar Fonti & Auld LLP said it filed a securities fraud class action against Embecta Corp. (NASDAQ:EMBC) and executives, alleging misleading statements about the strength of its insulin pen needle category. The suit cites a May 5, 2026 stock drop of 57.8% after Q2 results missed guidance, and notes a lead plaintiff deadline of Aug. 17, 2026.
4 min readFactSet says about 75% of S&P 500 companies reported Q2 results, with 85% beating analyst expectations. It estimates S&P 500 earnings up 50.4% year over year and revenue up about 15%, versus 12.2% expected. The article lists multiple stocks with EPS above consensus, including ESNT, FLR, TILE, and UAA.
6 min read
